Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Immunomodulating Agents

The enrolled subjects will receive SBRT treatment combined with Puterizumab.

The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.

Stereotactic Body Radiation Therapy，SBRT

Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).

Puterizumab

Xiaonan Sun, Ph D

Xuyun Xie, MD

This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy. Through single-cell sequencing and spatial transcriptome information analysis, the underlying mechanisms will be analyzed to provide a basis for improving the new precision treatment methods for tumor immunotherapy resistance.

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

The Efficacy and Safety of Stereotactic Radiotherapy Combined With Puterizumab in Non Small Cell Lung Cancer With Intrapulmonary Metastasis：A Phase II Prospective Single Arm Clinical Study

After the research is completed, the statistical results will be published as an article.

The tumor response rate will evaluate the local control of lung metastases，referring to the evaluation criteria for solid tumor efficacy RECIST 1.1

Using the minimal residual disease (MRD) panel for ctDNA molecular residual detection, and through ctDNA multi-node assessment, we can dynamically monitor the therapeutic efficacy and disease recurrence.

PFS is the time from enrollment to tumor progression or death.

OS is the time from enrollment to death due to any reason.

Refer to the acute radiation injury grading standards of the United States Collaborative Group on Tumor Radiotherapy (RTOG)

The quality of life will be evaluated using the QLQ-30 score.

Using flow cytometry to detect the count and percentage of lymphocytes, including CD3+, CD3+, CD4+, CD3+, CD8+, CD4+/CD8+, and CD3-CD56+.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC	NCT06434740	Non-Small-Cell ...	Stereotactic Bo... Puterizumab	18 Years -	Sir Run Run Shaw Hospital
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC	NCT06434740	Non-Small-Cell ...	Stereotactic Bo... Puterizumab	18 Years -	Sir Run Run Shaw Hospital

Spots Global Cancer Trial Database for puterizumab

Every month we try and update this database with for puterizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for puterizumab

Every month we try and update this database with for puterizumab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for puterizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.